AdvanCell
Summary active Updated Jul 16, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, operating a vertically integrated platform that combines proprietary Lead-212 (²¹²Pb) technology with isotope supply, advanced manufacturing, and clinical development 123. The company is co-headquartered in Boston, Massachusetts, and Brisbane, Australia, and was founded by Andrew Adamovich, who serves as Managing Director for Australia; Philina Lee, PhD was appointed CEO effective January 1, 2026 to lead U.S. expansion 14. Its lead clinical candidate, ADVC001 (²¹²Pb-ADVC001), is a PSMA-targeted alpha therapy in development for metastatic prostate cancer 123.
On 2026-07-15 AdvanCell announced an oversubscribed and upsized $315 million Series D financing led by Ally Bridge Group and co-led by Alpha Wave 123. New investors included Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price Associates, a leading sovereign wealth fund, Eventide Asset Management, and Velosity Capital 123. Existing investors Morningside, Eli Lilly and Company, SV Health Investors, Sanofi Ventures, Abingworth, SymBiosis, Tenmile, Brandon Capital, Piper Heartland, Catalio Capital Management, Proto Axiom, Time BioVentures, and other shareholders also participated 123. Proceeds will advance ADVC001 toward Phase 3 development, expand the Lead-212 platform, and strengthen U.S. manufacturing infrastructure 123.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-15 | Series D | $315M | Ally Bridge Group (lead), Alpha Wave (co-lead) | Bain Capital Life Sciences, Fidelity Management & Research, T. Rowe Price Associates, Eventide Asset Management, Velosity Capital, Morningside, Eli Lilly, SV Health Investors, Sanofi Ventures, Abingworth, SymBiosis, Tenmile, Brandon Capital, Piper Heartland, Catalio Capital Management, Proto Axiom, Time BioVentures 123 |
What Investors Say
No independently sourced investor quotes found at time of publication.
What Founders Say
No independently sourced founder testimonials found at time of publication.
Sources
-
“AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure,” AdvanCell press release, July 15, 2026. Accessed July 16, 2026. https://www.advancell.com.au/news/advancell-closes-us-315-million-oversubscribed-series-d-financing-to-advance-targeted-alpha-therapies-and-expand-clinical-and-commercial-manufacturing-infrastructure/↩↩↩↩↩↩↩↩
-
“AdvanCell Closes US $315M in Series D Funding,” FinSMEs, July 15, 2026. Accessed July 16, 2026. https://www.finsmes.com/2026/07/advancell-closes-us-315m-in-series-d-funding.html↩↩↩↩↩↩↩
-
“AdvanCell, T. Rowe Price Associates Back $315M Financing to Expand Targeted Alpha Therapy Platform,” citybiz, July 15, 2026. Accessed July 16, 2026. https://www.citybiz.co/article/874467/advancell-t-rowe-price-associates-back-315m-financing-to-expand-targeted-alpha-therapy-platform/↩↩↩↩↩↩↩
-
“AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth,” AdvanCell press release. Accessed July 16, 2026. https://www.advancell.com.au/news/advancell-appoints-philina-lee-phd-as-chief-executive-officer-to-lead-us-expansion-and-drive-global-growth/↩